CC
Corey Cutler
Scientific Advisory Board Member, Assoc. Prof. Harvard Medical School
Cimeio TherapeuticsTherapeutic Areas
Cimeio Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CD45 ADC + Shielded HSCs | Blood Cancers (e.g., Acute Myeloid Leukemia) | Pre-clinical |
| CD52 Shielding Platform | Hematologic Malignancies, Autoimmune Disorders | Pre-clinical |
| CD33 Shielding Platform | Hematologic Malignancies (e.g., AML) | Pre-clinical |
| Novel Cell Therapy (Kyowa Kirin Collab.) | Undisclosed Diseases with High Unmet Need | Research |
Leadership Team at Cimeio Therapeutics
LJ
Lukas Jeker
Founder, SVP Gene Editing Technology
SU
Stefanie Urlinger
Chief Scientific Officer
DS
Daniel Stark
Chief Manufacturing Officer
NS
Nikita Sharma
Head of Business Development
SA
Suneet Agarwal
Scientific Advisory Board Member, Assoc. Prof. Harvard Medical School
JB
Jeff Bluestone
Scientific Advisory Board Member, CEO, Sonoma Bio
FU
Fyodor Urnov
Scientific Advisory Board Chair, Prof. University of California Berkeley
ME
Markus Enzelberger
Independent Director, Board of Directors
AM
Alexander Mayweg
Chairman of the Board, Board of Directors
JB
Julie Brault
Team Member